let-7和HMGA2在肺癌发生发展中作用的Meta分析

doi:10.13481/j.1671-587x.20160614

Abstract

Abstract:

Objective: To evaluate the role of low expression of let-7 in the prognosis of lung cancer and the clinical significance of relationship between the HMGA2 expression and lung cancer by Meta-analysis method.Methods: The studies about the correlation between the low expression of let-7 and the prognosis of lung cancer and the correlation between the HMGA2 expression and the occurrence and development of lung cancer were collected by searching PubMed,Web of Science,Medline,Cochrane Library,Google, Scholar,CNKI,CBM,and Wanfang,and VIP databases.The StataSE 12.0 software was used for this Meta-analysis.Results: A total of 10 studies about the relationship between the low expression of let-7 and the prognosis of lung cancer (the patients with non-small cell lung cancer) were enrolled in this Meta-analysis.The low expression of let-7 indicated a poor overall survival rate,and the combined value of hazard ratio(HR) was 1.55 (95%CI:1.16-2.09,P<0.05).A total of 9 case-control studies about the relatlonship between the expression of HMGA2 and the occurrence and development of non-small cell lung cancer were selected for this Meta-analysis. The positive expression rate of HMGA2 in lung cancer tissue was significantly higher than that in paracancer normal tissue(OR=5.92,95% CI:3.96-8.85,P=0.000).The expression of HMAG2 in lung cancer tissue was pasitively related with the TNM stage and the lymph node metastasis of the patients(OR=0.26,95%CI:0.16-0.41,P<0.05;OR=0.29,95%CI:0.12-0.71,P<0.05).Conclusion: The low expression of let-7 is closely related to the poor prognosis of lung cancer patients.The highly positive expression rate of HMGA2 in lung cancer tissue is positively correlated with the occurrence and invasiveness of lung cancer.

Key words: lung neoplasms, prognosis, let-7, Meta-analysis, high mobility group A2

CLC Number:

R734.2

LI Xingxing, TAN Jingjin, JIANG Shan, WAHG Ke. Role of let-7 and HMGA2 in occurrence and development of lung cancer: Meta-analysis[J].Journal of Jilin University Medicine Edition, 2016, 42(06): 1116-1125.

References

[1] Shell S,Park SM,Radjabi AR,et al.Let-7 expression defines two differentiation stages of cancer[J].Proc Natl Acad Sci U S A,2007,104(27):11400-11405.
[2] Califano D,Pignata S,Losito NS,et al.High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer[J].J Cell Physiol,2014,229(1):53-59.
[3] Kong D,Su G,Zha L,et al.Coexpression of HMGA2 and Oct4 predicts an unfavorable prognosis in human gastric cancer[J].Med Oncol,2014,31(8):130.
[4] Takamizawa J,Konishi H,Yanagisawa K,et al.Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival[J].Cancer Res,2004,64(11):3753-3756.
[5] Inamura K,Togashi Y,Nomura K,et al.Let-7 microRNA expression is reduced in bronchioloalveolar carcinoma,a non-invasive carcinoma,and is not correlated with prognosis[J].Lung Cancer,2007,58(3):392-396.
[6] 严晓梅,冯一中,胥传海,等.微RNAlet7、高迁移率族蛋白在非小细胞肺癌中的表达及临床意义[J].江苏医药,2011,37(3):294-297.
[7] 杨大运,齐战,高少伟,等.HMGA2和RKIP在非小细胞肺癌中的表达及其相关性[J].现代预防医学,2015,9:1673-1676.
[8] Xia Y,Zhu Y,Zhou X,et al.Low expression of let-7 predicts poor prognosis in patients with multiple cancers:a Meta-analysis[J].Tumour Biol,2014,35(6):5143-5148.
[9] Blom IE,Goldschmeding R,Leask A.Gene regulation of connective tissue growth factor:new targets for antifibrotic therapy?[J].Matrix Biol,2002,21(6):473-482.
[10] Zhou ZR,Zhang T,Li B.Extracting and transforming of appropriate data of Meta-analysis in survival curve[J].Chin J Evid Based Cardiovasc Med,2014,6:3.
[11] Nair VS,Maeda LS,Ioannidis JP.Clinical outcome prediction by microRNAs in human cancer:a systematic review[J].Nair VS,2012,104(7):528-540.
[12] Voortman J,Goto A,Mendiboure J,et al.MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma[J].Cancer Res,2010,70(21):8288-8298.
[13] Zhao B,Han H,Chen J,et al.MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3[J].Cancer Lett,2014,342(1):43-51.
[14] Droge P,Davey CA.Do cells let-7 determine stemness?[J].Cell Stem Cell,2008,2(1):8-9.
[15] Mayr C,Hemann MT,Bartel DP.Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation[J].Science,2007,315(5818):1576-1579.
[16] He XY,Chen JX,Zhang Z,et al.The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice[J].J Cancer Res Clin Oncol,2010,136(7):1023-1028.
[17] Trang P,Wiggins JF,Daige CL,et al.Systemic delivery of tumor suppressor microRNA mimics using a nutral lipid emulsion inhibits lung tumors in mice[J].Mol Ther,2011,19(6):1116-1122.
[18] Helmke BM,Markowski DN,Meyer A,et al.The expression of HMGA2 varies strongly among colon carcinomas[J].Anticancer Res,2012,32(5):1589-1593.
[19] Muller MH,Drieschner N,Focken T,et al.HMGA2 expression in the PC-3 prostate cancer cell line is autonomous of growth factor stimulation[J].Anticancer Res,2013,33(8):3069-3078.
[20] Sun M,Song CX,Huang H,et al.HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis[J].Proc Natl Acad Sci U S A,2013,110(24):9920-9925.
[21] Kumar MS,Armenteros-Monterroso E,East P,et al.HMGA2 functions as a competing endogenous RNA to promote lung cancer progression[J].Nature,2014,505(7482):212-217.
[22] Rice SJ,Lai SC,Wood LW,et al.MicroRNA-33a mediates the regulation of high mobility group AT-hook 2 gene (HMGA2) by thyroid transcription factor 1(TTF-1/NKX2-1)[J].J Biol Chem,2013,288(23):16348-16360.
[23] Winslow MM,Dayton TL,Verhaak RG,et al.Suppression of lung adenocarcinoma progression by Nkx2-1[J].Nature,2011,473(7345):101-104.
[24] Xia XM,Jin WY,Shi RZ,et al.Clinical significance and the correlation of expression between Let-7 and K-ras in non-small cell lung cancer[J].Oncol Lett,2010,1(6):1045-1047.
[25] Landi MT,Zhao Y,Rotunno M,et al.MicroRNA expression differentiates histology and predicts survival of lung cancer[J].Clin Cancer Res,2010,16(2):430-441.
[26] Zhang YK,Zhu WY,He JY,et al.MiRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes[J].J Cancer Res Clin Oncol,2012,138(10):1641-1650.
[27] Yanaihara N,Caplen N,Bowman E,et al.Unique microRNA molecular profiles in lung cancer diagnosis and prognosis[J].Cancer Cell,2006,9(3):189-198.
[28] Jusufovic E,Rijavec M,Keser D,et al.let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non-small-cell lung cancer[J].PLoS One,2012,7(9):e45577.
[29] Capodanno A,Boldrini L,Proietti A,et al.Let-7g and miR-21 expression in non-small cell lung cancer:correlation with clinicopathological and molecular features[J].Int J Oncol,2013,43(3):765-774.
[30] 兰芬,熊盛道,熊维宁,等.非小细胞肺癌中HMGA2的表达与细胞增殖的关系[J].中国组织化学与细胞化学杂志,2008,17(5):416-420.
[31] 刘晓静,赵伟,张庆宪.HMGA2、MMP2在非小细胞肺癌中的表达及临床意义[J].中国老年学杂志,2011,31(2):209-211.
[32] 肖晓辉,刘华,高婧.高迁移率族蛋白A2和肿瘤转移抑制基因在非小细胞肺癌组织的表达及临床意义[J].临床荟萃,2013,28(2):138-140.
[33] Meyer B,Loeschke S,Schultze A,et al.HMGA2 overexpression in non-small cell lung cancer[J].Mol Carcinog,2007,46(7):503-511.
[34] Wu Y,Song Y,Liu H.Expression and its clinical significance of HMGA2 in the patients with non-small cell lung cancer[J].Chin J Lung Cancer,2008,11(3):377-381.
[35] Eide HA,Halvorsen AR,Bjaanaes MM,et al.The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma-differences in histological subtypes[J].BMC Cancer,2015,16(1):71.
[36] Sarhadi VK,Wikman H,Salmenkivi K,et al.Increased expression of high mobility group A proteins in lung cancer[J].J Pathol,2006,209(2):206-212.

Role of let-7 and HMGA2 in occurrence and development of lung cancer: Meta-analysis

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 5

[1]	QI Lu, BAI Wei, YU Weiying, LI Yuanyuan, HUA Wanqing, KOU Changgui. Randomized controlled trials for curative effect of saxagliptin combined with insulin in treatment of patients with type 2 diabetes mellitus: Meta-analysis [J]. Journal of Jilin University(Medicine Edition), 2018, 44(06): 1235-1242.
[2]	ZHU Guangwei, ZHENG Wei, HUANG Yongjian, HUA Jin, YANG Shugang, YE Jianxin. Expression of MyD88 in cancer tissue of patients with colorectal cancer and clinical significance [J]. Journal of Jilin University(Medicine Edition), 2018, 44(05): 1047-1051.
[3]	ZHANG Tao, ZHANG Guoming, YAN Fei, LIU Zheng, HUO Qiang. Values of evaluation of heart rate variability in major adverse cardiac events in patients with acute myocardial infarction after PCI [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 780-785.
[4]	YU Yunhe, DU Ye, HAN Bing, LI Sijie, SONG Lelian, FAN Zhimin. Observation on curative effects of neoadjuvant chemotherapy for different subtypes of Luminal B breast cancer and analysis on its prognosis [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 356-362.
[5]	FAN Liwen, FU Tong, GU Lin, WU Di, JIA Hongyao, SONG Dong. Accessory breast cancer: A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 412-415.
[6]	NIU Huikun, QU Yangming, LI Meiqi, LI Lu, LYU Xin, SONG Yuanyuan, GAO Chunshi, LI Bo. Meta-analysis on efficacy and adverse effects of neoadjuvant chemotherapy combined with capecitabine in treatment of breast cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(06): 1171-1176.
[7]	SUN Huiying, Du Bo, YU Zhi, LIU Hongquan, YU Hong. Clinical analysis on sudden sensorineural hearing loss complicated with BPPV and literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 1025-1029.
[8]	YAO Yanan, YAO Hua, YAN Duoduo, LYU Kejia, GONG Lijun, WANG Guohua. Meta-analysis on correlation between oral lichen planus and Candida albicans infection [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 967-974.
[9]	LIU Xiangliang, JI Wei, LI Li, ZHAO Yinghua, JIA Lin, WANG Zhiqiang, CHEN Xiao, LI Wei. Lung adenocarcinoma treated by Erlotinib HCL Tablets and chemotherapy combined with bevacizumab after drug resistance:A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 1019-1024.
[10]	SU Junyan, LI Yingjin, XU Changyan. Influence of CD96 and CD71 expressions in surface of leukemia stem cells in therapeutic effects and prognosis of children with acute leukemia [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 776-781.
[11]	NIU Meng, DENG Dayong, LI Yunpengfei, LIU Shuo, DING Jun. Values of MRE in diagnosis of stages of hepatic fibrosis:A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 787-793.
[12]	YANG Dongyang, LAI Xiaorong, LI Ying, MA Liyu, LUO Gang, LI Zijun, XU Fei, MA Dong. Influence of primary resection and KRAS gene mutation in prognosis of mild symptomatic patients with stage Ⅳ colorectal cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 805-811.
[13]	XIAO Yan, WANG Huan, WANG Shumin, GAO Ying. Lung cancer complicated with syndrome of inappropriate secretion of antidiuretic hormone:A report of 2 cases and literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(03): 643-645.
[14]	MA Ranyang, YU Hong, WANG Xin. Evaluation on clinical efficacy of hyperbaric oxygenation in treatment of sudden deafness:A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 298-305.
[15]	ZHANG Yang, WANG Junfeng, CAOHongyan, QIN Ling, XU Guoliang. Effectiveness and safety of Dengzhanhuasu and Dansheng Injection in treatment of patients with angina pectoris of coronary heart disease:A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 317-321.